September 2025: Relief of Arthritis The African food supplement being investigated for sickle cell treatment, is used traditionally for arthritis treatment. This was discounted initially, as our focus was on sickle cell disease. However, when chemical analysis identified the active compounds in the plant, one group was recognised as having potential for alleviating arthritis. A separate Phase 1 trial was conducted with patients having from mild osteoarthritis to severe rheumatoid arthritis, with spectacular results in both groups. An independent Phase 2 double blind trial is scheduled for 2026 in humans, and at separate trial for its use with dogs.

January 2025: Sickle Cell Treatment Our production of the plant material required for our  sickle cell treatment is being ramped up for a Phase 3 double blind cross-over trial in 2025/26.  A total of 80 acres of land has been purchased to grow the plants, with a dedicated staff of ten full time people providing the husbandry.

October 2024: Ventilator Validation Deep Life Group's UK arm, Open Safety Equipment Ltd, has released its latest respiratory simulator, iBreathe MkIV, providing automated tested of VWAICO2, WOB and other key parameters in real time. This tool provides rapid validation of ventilator performance. For more information: Click here

February 2024: Phase 2 Clinical Trial Success for Anugel(™) A randomised clinical tria completed in on 110 patients, found that Anugel(™) cuts the need for analgesics following surgery, and the product is now progressing to certification. For more information: Click here